Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 November 1992Website:
http://www.navidea.comNext earnings report:
03 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
NAVB Latest News
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii.
Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE American LLC sent the company a notice about its failure to comply with listing standards.
Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.
What type of business is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
What sector is Navidea Biopharmaceuticals in?
Navidea Biopharmaceuticals is in the Healthcare sector
What industry is Navidea Biopharmaceuticals in?
Navidea Biopharmaceuticals is in the Biotechnology industry
What country is Navidea Biopharmaceuticals from?
Navidea Biopharmaceuticals is headquartered in United States
When did Navidea Biopharmaceuticals go public?
Navidea Biopharmaceuticals initial public offering (IPO) was on 10 November 1992
What is Navidea Biopharmaceuticals website?
https://www.navidea.com
Is Navidea Biopharmaceuticals in the S&P 500?
No, Navidea Biopharmaceuticals is not included in the S&P 500 index
Is Navidea Biopharmaceuticals in the NASDAQ 100?
No, Navidea Biopharmaceuticals is not included in the NASDAQ 100 index
Is Navidea Biopharmaceuticals in the Dow Jones?
No, Navidea Biopharmaceuticals is not included in the Dow Jones index
When does Navidea Biopharmaceuticals report earnings?
The next expected earnings date for Navidea Biopharmaceuticals is 03 July 2024